English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

every 2 weeks) and placebo for 52 weeks in patients on stable statin therapy. Alirocumab reduced the LDL-C levels by more than 60%, to 53.5 and 53.4 mg/dl at 24 and 52 weeks, respectively. The LDL-lowering effect was sustained to the endpoint of week 52, and no rebound effect was observed. Also, alirocumab markedly reduced non-HDL cholesterol and apolipoprotein B levels. In some cases, the LDL-C level was ow-density lipoprotein cholesterol (LDL-C) is a wellestablished causative risk factor for coronary artery disease (CAD), and intensive LDL-lowering treatment with statins has efficiently reduced coronary events and deaths.1 Nevertheless, many patients in Japan with high coronary risk have not achieved LDL-C target goals.2 Furthermore, clinical trials suggest that residual risks remain for CAD even with maximal potency statins.3 Additional reduction in LDL-C, to <60 mg/dl, using the non-statin drug, ezetimibe, has been shown in recent years to result in a further reduction of cardiovascular events.4 However, as it has already been 30 years after the introduction of statins and 10 years after ezetimibe came onto the market, it is time for the next breakthrough.

Dawn of a New Era – The Far Lower, the Far Better Low-Density Lipoprotein Cholesterol Story in Japan –